Skip to Content

Evotec SE ADR EVO Stock Quote

| Rating as of


Last close prices updated as of May 31, 2023, 11:55 AM EST | USD | BATS BZX Real-Time Price
  • Last Close 10.66
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Investment Style Mid Growth
  • Day Range 10.61  –  10.81
  • Year Range 7.80  –  15.04
  • Market Cap 3.8080 Bil
  • Volume / Avg 6,626.0 /  33,623.6
  • Price / Sales 4.68
  • Price / Book 2.96
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis EVO

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics EVO

Company Profile EVO

Business Description

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Essener Bogen 7, Manfred Eigen Campus
Hamburg, 22419, DEU
Industry Drug Manufacturers - Specialty & Generic
Employees 4,952

Competitors & Peers EVO

Morningstar does not cover competitors or peers for this firm.

FAQs for Evotec SE ADR Stock

No. EVO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

EVO’s market cap is 3.81 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

EVO’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

EVO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare EVO’s historical performance against its industry peers and the overall market.